Ketamine One Capital Limited (NEO:MEDI) (OTCMKTS:KONEF) (FRA:MY0) has appointed Adam Deffett as its interim CEO.
Deffett, who is also vice president of capital markets, will retain both positions as the company continues to consolidate medical clinics in an effort to become a North American leader in mental health treatments.
As part of Ketamine’s updated strategy, the company changed its name from Myconic Capital, to Ketamine One in June.
READ: Wall Street moves into the green in early deals as traders eye Fed minutes
Former CEO Robert Meister has stepped down and also resigned from the board to facilitate the company’s pursuit of its new strategy. The metal health-focused firm is now in the process of identifying appropriate candidates with the goal of hiring a permanent CEO in the coming months.
After starting his career at RBC Capital Markets, Deffett will bring his more than 15 years experience in the Canadian equity markets to his new role. The interim CEO has also held senior positions in both sales and trading at various Canadian banks and independent dealers.
Commenting on his appointment, Deffett offered the following in a statement: “I would like to thank Robert for stewarding the transition of the company from an investment issuer under the name of Myconic Capital Corp to a company dedicated to mental healthcare and the rebrand to Ketamine One."
He went on to say: “I greatly appreciate the opportunity to lead Ketamine One during this exciting time as we execute on our vision of becoming a leader in mental health and wellness across North America. We are fortunate to have a leadership team with great depth, decades of operating experience and detailed knowledge of our businesses. Our team is working hard to establish Ketamine One as the preeminent mental health platform for patients, by aggregating existing medical clinics and establishing new locations, while supporting KGK Science as a leading clinical research organization and implementing leading technologies throughout the organization wherever possible.”
In consideration of Deffett’s appointment, Ketamine One has granted an aggregate of 200,000 stock options to purchase up to 200,000 common shares of the company at a price of $1.55 per common share for a period of five years from the date of issuance.
Contact the writer at georgia@proactiveinvestors.com
Follow her on Twitter @MissInformd